尤瑞克林治疗急性脑梗死的临床疗效及对血清高敏C-反应蛋白水平的影响

Curative effect of Urinary Kallidinogenase on changes of serum high sensitivity C-reactive protein in patients with acute cerebral infarction

目的探讨尤瑞克林治疗急性脑梗死的临床疗效及对血清高敏C-反应蛋白(hs-CRP)的水平影响。方法将102例急性脑梗死患者随机分为治疗组、对照组,每组51例,对照组给予常规治疗,治疗组在常规治疗的基础上加用尤瑞克林,共14d,2组治疗前后分别测血清hs-CRP水平浓度,并观察其神经功能缺损评分变化。结果治疗后2组神经功能缺损评分较治疗前均有改善,但治疗组明显优于对照组(P<0.01);治疗后2组hs-CRP较治疗前均有降低,但治疗组较对照组显著降低(P<0.01)。治疗期间无明显不良反应发生。结论尤瑞克林治疗急性脑梗死安全有效,且可显著降低急性脑梗死患者血清hs-CRP水平浓度,对改善脑梗死病情有重要意义。

Objective To investigate the clinical curative effect of Urinary Kallidinogenase on the changes of serum high sensitivity C-reactive protein （hs-CRP） in patients with acute cerebral infarction（ACI）. Methods One hundred and two cases of acute cerebral infarction patients were randomly divided into two groups： treatment group and control group. Both group were given cerebral nervenutriceutical and antiplatelet routine treatment. Urinary Kallidinogenase was additionally used in the treatment group. The neurologic impairment scores and serum level of hs-CRP pretreatment and on the 14th day post-treatment were compared in two groups. Results Neurologic impairment scores of two groups were all improved, but the treatment group was better than control group （P〈0.01）. Serum levels of hs-CRP were reduced in the two groups, hut the treatment group was significantly lower than control group （P〈0.01）. There was no obvious adverse reaction. Conclusion Urinary Kallidinogenase in the treatment of acute cerebral infarction is safe and effective, and can significantly reduce the serum concen- trations of CRP, and has important significances in improving cerebral infarction illness.